Return to full-intensity training too soon risks re-injury or chronic damage
Risk factors that may prompt additional consideration include: Active gastrointestinal symptoms (nausea, vomiting, abdominal pain) Recent dose increases or being in the dose-escalation phase Higher doses of semaglutide Known gastroparesis or other conditions affecting gastric emptying Obesity with GERD or hiatal hernia Based on the 2024 multi-society guidance, most patients can continue GLP-1 receptor agonists before elective procedures with appropriate risk assessment and mitigation strategies, rather than automatic postponement
21,22 However, no association was found between pancreatitis and use of GLP-1RAs in the randomised controlled cardiovascular outcome trials, meta-analyses and systematic reviews
Meanwhile, existing treatments for other conditions could be repurposed for weight loss
Medications like proton pump inhibitors (PPIs) and H2 blockers can help reduce acid and protect the esophagus
Is Flatter Me Fiber made in an FDA-approved facility
